Interference of glucocorticoids with apoptosis signaling and host-tumor interactions

Cancer Biology and Therapy

Volumn 3, Issue 8, 2004, Pages 715-718

  Rutz, Hans Peter ^a   Herr, Ingrid ^b  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cachexia; Cancer; Chemotherapy; Dexamethasone; Failure; Prednisone; Radiation therapy; Resistance

Indexed keywords

GLUCOCORTICOID;

APOPTOSIS; CANCER; CANCER CELL; CANCER PATIENT; CYTOTOXICITY; DIABETES MELLITUS; GLUCOSE METABOLISM; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TUMOR IMMUNITY; DRUG EFFECT; DRUG INTERACTION; METABOLISM; NEOPLASM; PATHOLOGY;

APOPTOSIS; DIABETES MELLITUS; DRUG INTERACTIONS; GLUCOCORTICOIDS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 16644383569     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.8.966     Document Type: Review

References (89)

1. Karin M, Herschman HR. Dexamethasone stimulation of metallothionein synthesis in HeLa cell cultures. Science 1979; 204:176-7.
2. Rutz HP, Mariotta M, Mirimanoff RO. Dexamethasone-induced cross-enhancement of resistance to radiation and cisplatin. Schweiz Med Wschr 1992; 122:35S.
3. Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002; 360:1969-70.
4. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, et al. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003; 63:3112-20.
5. Rutz HP. A biophysical basis of enhanced interstitial fluid pressure in tumors. Med Hypotheses 1999; 53:520-9.
6. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267:1445-9.
7. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1985; 267:1456-62.
8. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994; 78:539-42.
9. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256:42-9.
10. Assuncao Guimaraes C, Linden R. Programmed cell deaths. Eur J Biochem 2004; 271:1638-50.
11. Smith GB, Weinstock LM, Roberts FE Jr, Brenner GS, Hoinowski AM, Arison BH, et al. Kinetics of equilibrium of bisulfate and dexamethasone-21-phosphate in aqueous solution. J Pharm Sci 1972;61:708-16.
12. Sloman JC, Murphy Jr MJ. Dexamethasone-induced increase in in vitro clonogenicity of human neoplasms. J Clin Oncol 1984; 2:944-7.
13. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001; 276:16649-54.
14. Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J. Dexamethasone inhibits TNF-α-induced apoptosis and IAP protein downregulation in MCF-7 cells. Br J Pharmacol 2001; 133:467-76.
15. Marietta M, Perewusnyk G, Koechli OR, Little JB, von Knebel Doeberitz M, Mirimanoff RO, et al. Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells. Strahlenther Onkol 1999; 175:392-6.
16. Kamradt MC, Mohideen N, Krueger E, Walter S, Vaughan AT. Inhibition of radiation-induced apoptosis by dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6/E7. Br J Cancer 2000; 82:1709-16.
17. Kamradt MC, Walter S, Koudelik J, Shafer L, Weijzen S, Velders M, et al. Steroid-mediated inhibition of radiation-induced apoptosis in C4-1 cervical carcinoma cells is p53-dependent. Eur J Cancer 2001; 37:2240-6.
18. Rutz HP, Mariotta M, von Knebel Doeberitz M, Mirimanoff RO. Dexamethasone-induced radioresistance occurring independent of human papilloma virus gene expression in cervical carcinoma cells. Strahlenther Onkol 1998; 174:71-4.
19. Chang TC, Hung MW, Jiang SY, Chu JT, Chu LL, Tsai LC. Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression. FEBS Lett 1997; 415:11-5.
20. Evans-Storms RB, Cidlowski JA. Delineation of an antiapoptotic action of glucocorticoids in hepatoma cells: The role of nuclear factor-kappaB. Endocrinology 2000; 141:1854-62.
21. Bergman AM, Pinedo HM, Peters GJ. Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur J Pharmacol 2001; 416:19-24.
22. Sloman JC, Murphy Jr MJ. Dexamethasone-induced increase in in vitro clonogenicity of human neoplasms. J Clin Oncol 1984; 2:944-7.
23. Carollo M, Parente L, D'Alessandro N. Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1. Oncol Res 1998; 10:245-54.
24. Kruit A, Reyes-Moreno C, Newling DW, Geldof A, Koutsilieris M. Response of PC-3 prostate cancer cells to combination therapy using irradiation with glucocorticoids or doxorubicin. Anticancer Res 1999; 19:3153-6.
25. Chang CY, Walther PJ, McDonnell DP. Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 2001; 61:8712-7.
26. Uozumi J, Koikawa Y, Yasumasu T, Tokuda N, Kumazawa J. The protective effect of methylprednisolone against cisplatin-induced nephrotoxicity in patients with urothelial tumors. Int J Urol 1996; 3:343-7.
27. Newton CJ, Bilko D, Pappa S, Atkin SL. Dexamethasone blocks antioestrogen- and oxidant-induced death of pituitary tumour cells. J Endocrinol 2001; 169:249-61.
28. Weller M, Schmidt C, Roth W, Dichgans J. Chemotherapy of human malignant glioma: Prevention of efficacy by dexamethasone? Neurology 1997; 48:1704-9.
29. Wolff JE, Denecke J, Jurgens H. Dexamethasone induces partial resistance to cisplatinum in C6 glioma cells. Anticancer Res 1996; 16:805-9.
30. Gorman AM, Hirt UA, Orrenius S, Ceccatelli S. Dexamethasone pretreatment interferes with apoptotic death in glioma cells. Neuroscience 2000; 96:417-25.
31. Benedetti S, Pirola B, Poliani PL, Cajola L, Pollo B, Bagnati R, et al. Dexamethasone inhibits the anti-tumor effect of interleukin 4 on rat experimental gliomas. Gene Ther 2003; 10:188-92.
32. Wolff JE, Jurgens H. Dexamethasone induced partial resistance to methotrexate in C6-glioma cells. Anticancer Res 1994; 14:1585-8.
33. Zibera C, Gibelli N, Butti G, et al. Proliferative effect of dexamethasone on a human glioblastoma cell line (HU 197) is mediated by glucocorticoid receptors. Anticancer Res 1992; 12:1571-4. AUTHOR: please complete authors up to 6 names, et al.
34. Rieger J, Durka S, Streffer J, Dichgans J, Weller M. Gemcitabine cytotoxicity of human malignant glioma cells: Modulation by antioxidants, BCL-2 and dexamethasone. Eur J Pharmacol 1999; 365:301-8.
35. WAF1/CIP1 protein accumulation? Oncogene 1998; 17:1567-75.
36. Chaudhuri PK, Das Gupta TK, Beattie CW, Walker MJ. Glucocorticoid-induced exacerbation of metastatic human melanoma. J Surg Oncol 1982; 20:49-52.
37. Sengupta S, Vonesch JL, Waltzinger C, Zheng H, Wasylyk B. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J 2000; 19:6051-64.
38. Kofler R. The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem Cell Biol 2000; 114:1-7.
39. Planey SL, Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 2000; 279:307-12.
40. Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002; 9:6-19.
41. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004; 64:1757-64.
42. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295:2465-8.
43. Herr I, Debatin K-M. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98:2603-14.
44. Liden J, Delaunay F, Rafter I, Gustafsson J, Okret S. A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J Biol Chem 1997; 272:21467-72.
45. Liden J, Rafter I, Truss M, Gustafsson JA, Okret S. Glucocorticoid effects on NF-κB binding in the transcription of the ICAM-1 gene. Biochem Biophys Res Commun 2000; 273:1008-14.
46. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000; 60:4426-32.
47. Sasson R, Amsterdam A. Pleiotropic anti-apoptotic activity of glucocorticoids in ovarian follicular cells. Biochem Pharmacol 2003; 66:1393-401.
48. Sasson R, Shinder V, Dantes A, Land A, Amsterdam A. Activation of multiple signal transduction pathways by glucocorticoids: Protection of ovarian follicular cells against apoptosis. Biochem Biophys Res Commun 2003; 311:1047-56.
49. Hallahan DE, Spriggs DR, Becket MA, Kufe DE, Weichselbaum RR. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA 1989; 86:10104-7.
50. Hallahan DE, Virudachalam S, Kuchibothla J, Kufe DE, Weichselbaum RR. Membrane-derived second messengers regulate x-ray-mediated TNF gene induction. Proc Natl Acad Sci USA 1994; 91:4897-901.
51. Hallahan DE, Beckett MA, Kufe D, Weichselbaum RR. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys 1990; 19:69-74.
52. Herr I, Wilhelm D, Boehler T, Angel P, Debatin K-M. JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-a. Int J Cancer 1999; 80:417-24.
53. Haid M. Steroid antiemesis may be harmful. N Engl J Med 1981; 304:1237.
54. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411:1058-64.
55. Bansal N, Houle A, Melnykovych G. Apoptosis: Mode of cell death induced in T cell leukemia lines by dexamethasone and other agents. FASEB J 1991; 5:211-6.
56. Nieto MA, Gonzalez A, Gambon F, Diaz-Espada F, Lopez-Rivas A. Apoptosis in human thymocytes after treatment with glucocorticoids. Clin Exp Immunol 1992; 88:341-4.
57. Adebodun F, Post JF. 19F NMR studies of changes in membrane potential and intracellular volume during dexamethasone-induced apoptosis in human leukemic cell lines. J Cell Physiol 1993; 154:199-206.
58. Migliorati G, Nicoletti I, D'Adamio F, Spreca A, Pagliacci C, Riccardi C. Dexamethasone induces apoptosis in mouse natural killer cells and cytotoxic T lymphocytes. Immunology 1994; 81:21-6.
59. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270:286-90.
60. Smets LA, van den Berg JD. Bcl-2 expression and glucocorticoid-induced apoptosis of leukemic and lymphoma cells. Leuk Lymphoma 1996; 20:199-205.
61. Cidlowski JA, King KL, Evans-Storms RB, Montague JW, Bortner CD, Hughes Jr FM. The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system. Recent Prog Horm Res 1996; 51:457-90.
62. Miyoshi H, Ohki M, Nakagawa T, Honma Y. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with A t(8;21) chromosome translocation. Leuk Res 1997; 21:45-50.
63. Pruschy M, Shi YQ, Crompton NE, Steinbach J, Aguzzi A, Glanzmann C, et al. The proto-oncogene c-fos mediates apoptosis in murine T-lymphocytes induced by ionizing radiation and dexamethasone. Biochem Biophys Res Commun 1997; 241:519-24.
64. Shenkerman G, Klaper R, Ness-Abramof R, Vishlitzky V, Zemer R, Ellis M, et al. Induction of apoptosis by chlorodeoxyadenosine and dexamethasone in B-chronic lymphocytic leukemia. Leuk Lymphoma 1997; 28:153-7.
65. Andreau K, Lemaire C, Souvannavong V, Adam A. Induction of apoptosis by dexamethasone in the B cell lineage. Immunopharmacology 1998; 40:67-76.
66. Schmidt M, Pauels HG, Lugering N, Lugering A, Domschke W, Kucharzik T. Glucocorticoids induce apoptosis in human monocytes: Potential role of IL-1 β. J Immunol 1999; 163:3484-90.
67. Arai Y, Nakamura Y, Inoue F, Yamamoto K, Saito K, Furusawa S. Glucocorticoid-induced apoptotic pathways in eosinophils: Comparison with glucocorticoid-sensitive leukemia cells. Int J Hematol 2000; 71:340-9.
68. Chen X, Murakami T, Oppenheim JJ, Howard OM. Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death. Eur J Immunol 2004; 34:859-69.
69. von Knebel Doeberitz M, Koch S, Drzonek H, Zur Hausen H. Glucocorticoid hormones reduce the expression of major histocompatibility class I antigens on human epithelial cells. Eur J Immunol 1990; 20:35-40.
70. Jusko WJ. Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Toxicology 1995; 102:189-96.
71. Todo T, Rabkin SD, Chahlavi A, Martuza RL. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther 1999; 10:2869-78.
72. Braithwaite SS, Barr WG, Rahman A, Quddusi S. Managing diabetes during glucocorticoid therapy. How to avoid metabolic emergencies. Postgrad Med 1998; 104:163-6, 71, 75-6.
73. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999; 25:489-505.
74. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, et al. 'The metabolism of tumours': 70 years later. Novartis Found Symp 2001; 240:251-60.
75. Jain RK. Transport of molecules in the interstitium: A review. Cancer Res 1987; 47:3039-51.
76. Jain RK, Baxter LT. Mechanism of heterogenous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 1988; 48:7022-32.
77. Boucher Y, Baxter TL, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Res 1990; 50:4478-84.
78. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK. Time-dependent behavior of interstitial fluid pressure in solid tumors: Implications for drug delivery. Cancer Res 1995; 55:5451-8.
79. Curti BD. Physical barriers to drug delivery in tumors. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996:709-19.
80. Rohdenburg GL, Barnhard A, Krehbiel O. Sugar tolerance in cancer. JAMA 1919; 72:1528-34.
81. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 1992; 11:445-56.
82. Tayek JA, Katz J. Glucose production, recycling, Cori cycle, and gluconeogenesis in humans: Relationship to serum cortisol. Am J Physiol 1997; 272:E476-84.
83. Tayek JA, Manglik S, Abemayor E. Insulin secretion, glucose production, and insulin sensitivity in underweight and normal-weight volunteers, and in underweight and normal-weight cancer patients: A clinical research center study. Metabolism 1997; 46:140-5.
84. Cheng L, Du C, Murray D, Tong X, Zhang YA, Chen BP, et al. A GFP reporter system to assess gene transfer and expression in human hematopoietic progenitor cells. Gene Ther 1997; 4:1013-22.
85. Aapro MS. Present role of corticosteroids as antiemetics. In: Recent results in cancer research. Berlin: Springer Verlag, 1991:91-100.
86. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332:1-5.
87. Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342:1554-9.
88. Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong R, et al. Dexamethasone for the prophylaxis of radiation-induced emesis: A National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 2000; 18:1960-6.
89. Ambrus JL, Halpern J, Baerwald H, Johnson RJ. Cyclo-oxygenase and lipo-oxygenase inhibitors may substitute for steroid treatment in brain oedema. Lancet 1985; 2:148-9.